NCT07046845 Perelel Prenatal Supplements vs. Generic Prenatal Supplements and Health of Mother and Baby (SUPPORT)
| NCT ID | NCT07046845 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Pregnancy |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2026-01-07 |
| Primary Completion | 2027-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2026-01-07 with a primary completion date of 2027-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if using Perelel-brand prenatal supplements versus a generic prenatal supplement improves the health of the mother and fetus (unborn baby) during pregnancy. The main question it aims to answer is: • How does taking Perelel prenatal supplements versus generic prenatal supplements during pregnancy change the nutritional markers in blood samples? Participants will: * Take either Perelel or generic prenatal supplements daily throughout pregnancy * Visit UPMC Magee-Womens Hospital once every trimester of pregnancy for blood draws and answering questionnaires In an observational part of this study for different participants, researchers will use blood tests and questionnaires only once during the first trimester to compare pregnant women without food insecurity to those with food insecurity.
Eligibility Criteria
Inclusion Criteria: 1. Pregnant with only one baby 2. Identify as having food insecurity 3. Receiving care at a Magee-Womens Hospital associated prenatal practice 4. Less than 12 weeks' of pregnancy Exclusion Criteria: 1. Currently using prenatal supplement(s) 2. Unborn baby (fetus) identified as having a chromosomal or structural defect 3. Have a condition that prevents absorption of nutrients from food 4. History of medically treated thyroid disorder 5. Ongoing steroid use
Contact & Investigator
Hyagriv Simhan, MD
PRINCIPAL INVESTIGATOR
Magee-Women's Research Institute
Frequently Asked Questions
Who can join the NCT07046845 clinical trial?
This trial is open to female participants only, aged 14 Years or older, studying Pregnancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07046845 currently recruiting?
Yes, NCT07046845 is actively recruiting participants. Contact the research team at tessje@upmc.edu for enrollment information.
Where is the NCT07046845 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT07046845 clinical trial?
NCT07046845 is sponsored by University of Pittsburgh. The principal investigator is Hyagriv Simhan, MD at Magee-Women's Research Institute. The trial plans to enroll 600 participants.